Investigation of regional mechanisms responsible for poor oral absorption in humans of a modified release preparation of the α-adrenoreceptor antagonist, 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): The rational use of ex vivo intestine to predict in vivo absorption

Drug Metabolism and Disposition

Volumn 36, Issue 1, 2008, Pages 87-94

  Collett, A ^a   Stephens, R H ^a   Harwood, M D ^a   Humphrey, M ^b   Dallman, L ^b   Bennett, J ^b   Davis, J ^b   Carlson, G L ^a   Warhurst, Geoffrey ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 6,7 DIMETHOXY 2 (5 METHANESULFONAMIDO 1,2,3,4 TETRAHYDROISOQUINOL 2 YL) 5 (2 PYRIDYL)QUINAZOLINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; UK 338003; UNCLASSIFIED DRUG;

ADULT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BASOLATERAL MEMBRANE; CELL STRAIN CACO 2; CLINICAL TRIAL; COLON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGESTIVE TRACT INTUBATION; DRUG ABSORPTION; DRUG FORMULATION; DRUG INHIBITION; DRUG RELEASE; DRUG RESEARCH; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; ILEUM; IN VIVO STUDY; INTESTINE; INTESTINE ABSORPTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEMBRANE PERMEABILITY; MONOLAYER CULTURE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ABSORPTION; ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ADRENERGIC ALPHA-ANTAGONISTS; ADULT; ANIMALS; CACO-2 CELLS; CHROMATOGRAPHY, LIQUID; COLON; DELAYED-ACTION PREPARATIONS; HUMANS; ILEUM; INTESTINAL ABSORPTION; INTESTINES; ISOQUINOLINES; MALE; MICE; MICE, KNOCKOUT; MOUTH MUCOSA; PREDICTIVE VALUE OF TESTS; RECEPTORS, ADRENERGIC, ALPHA; SULFONAMIDES; TANDEM MASS SPECTROMETRY;

EID: 37549050936     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.016865     Document Type: Article

References (34)

1. Abu-Qare AW, Elmasry E, and Abou-Donia MB (2003) A role for P-glycoprotein in environmental toxicology. J Toxicol Environ Health B Crit Rev 6:279-288.
2. Abushammala I, Garrigues TM, et al. (2006) Labetalol absorption kinetics: rat small intestine and colon studies. J Pharm Sci 95:1733-1741.
3. L-adrenoceptor antagonists. Drug Metab Dispos 35:1435-1445.
4. Bohets H, Annaert P, Mannens G, Van Beijsterveldt L, Anciaux K, Verboven P, Meuldermans W, and Lavrijsen K (2001) Strategies for absorption screening in drug discovery and development. Curr Top Med Chem 1:367-383.
5. Calcagno AM, Ludwig JA, Fostel JM, Gottesman MM, and Ambudkar SV (2006) Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery. Mol Pharm 3:87-93.
6. Conley R, Gupta SK, and Sathyan G (2006) Clinical spectrum of the osmotic-modified release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 10:1879-1892.
7. Davis SS, Hardy JG, and Fara JW (1986) Transit of pharmaceutical dosage forms through the small intestine. Gut 27:886-892.
8. Dey S (2006) Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition. Expert Opin Drug Deliv 3:23-35.
9. Eichenbaum G, Pollock-Dove C, Nguyen J, Li S, Evans J, Borghys H, Kennis L, Dong L, van Osdol W, Dai W, et al. (2006) Preclinical assessment of the feasibility of applying controlled release oral drug delivery to a lead series of atypical antipsychotics. J Pharm Sci 95:883-895.
10. Englund G, Rorsman F, Ronnblom A, Karlbom U, Lazorova L, Grasjo J, Kindmark A, and Artursson P (2006) Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 29:269-277.
11. 4 receptor antagonist MK571 specifically modulates MRP associated multidrug-resistance. Biochem Biophys Res Commun 208:345-352.
12. González MA and Straughan AB (1994) Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. Clin Ther 16:804-814.
13. Kim J-S, Mitchell S, Kijek P, Tsume Y, Hilfinger J, and Amidon GL (2006) The suitability of an in situ perfusion model for permeability determinations: utility for BCS Class I biowaiver requests. Mol Pharm 3:686-694.
14. Kirby RS, O'Leary P, and Culley C (2005) Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. BJU Int 9:103-109.
15. Lennernas H (1997) Human jejunal effective permeability and its correlation with preclinical drug absorption models. J Pharm Pharmacol 7:627-638.
16. Lin JH and Yamazaki M (2003) Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42:59-98.
17. Makhey VD, Guo A, Norris DA, Hu P, Yan J, and Sinko PJ (1998) Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharmacol Res 15:1160-1167.
18. Masaoka Y, Tanaka Y, Kataoka M, Sakuma S, and Yamashita S (2006) Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur J Pharm Sci 29:240-250.
19. McKinnon RA, Burgess WM, Hall PM, Roberts-Thomson SJ, González FJ, and McManus ME (1995) Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 36:259-267.
20. Rubas W, Cromwell ME, Shahrokh Z, Villagran J, Nguyen TN, Wellton M, Nguyen TH, and Mrsny RJ (1996) Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. J Pharm Sci 85:165-169.
21. Saitoh H and Aungst BJ (1995) Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharmacol Res 9:1304-1310.
22. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
23. Seithel A, Karlsson J, Hilgendorf C, Bjorquist A, and Ungell AL (2006) Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur J Pharm Sci 28:291-299.
24. Shah P, Jogani V, Bagchi T, and Misra A (2006) Role of Caco-2 cell monolayers in prediction of intestinal drug absorption. Biotechnol Prog 22:186-198.
25. Stephens RH, O'Neill CA, Bennett J, Humphrey M, Henry B, Rowland M, and Warhurst G (2002a) Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a(-/-) mice. Br J Pharmacol 135:2038-2046.
26. Stephens RH, Tanianis-Hughes J, Higgs NB, Humphrey M, and Warhust G (2002b) Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(-/-) mouse intestine. J Pharmacol Exp Ther 303:1095-1110.
27. Tan B, Piwnica-Worms D, and Ratner L (2000) Multidrug resistance transporters and modulation. Curr Opin Oncol 12:450-458.
28. Thombre AG (2005) Assessment of the feasibility of oral controlled release in an exploratory development setting. Drug Discov Today 10:1159-1166.
29. Tubic M, Wagner D, Spahn-Langguth H, Weiler C, Wanitschke R, Bocher WO, and Langguth P (2006) Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans. Eur J Pharm Sci 29:231-239.
30. Wagner D, Spahn-Langguth H, Hanafy A, Koggel A and Langguth P (2001) Intestinal drug efflux: formulation and food effects. Adv Drug Deliv Rev 50 (Suppl 1):S13-S31.
31. Wilding IR, Coupe AJ, and Davis SS (2001) The role of γ-scintigraphy in oral drug delivery. Adv Drug Deliv Rev 46:103-124.
32. Ungell AL, Nylander S, Bergstrand S, Sjoberg A, and Lennernas H (1998) Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci 87:360-3656.
33. Van Kerrebroeck PE (2001) The efficacy and safety of a new once-a-day formulation of an α-blocker. Eur Urol 39 (Suppl 6):19-26.
34. Zimmermann C, Gutmann H, Hruz P, Gutzwiller JP, Beglinger C, and Drewe J (2005) Mapping of multidrug resistance gene 1 and multidrug resistance- associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab Dispos 33:219-224.